References
Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008;28:1443–52.
Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.
Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20:177–84.
Kitamura M. Italy to fund unapproved use of roche drug to cut costs. In: Bloomberg News. 2014. http://www.bloomberg.com/news/2014-06-10/italy-to-fund-unapproved-use-of-roche-drug-to-cut-costs.html. Accessed 13 Aug 2014.
Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14:417–28.
Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429–37.
Palazzuoli A, Ruocco G, Pellegrini M, et al. The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag. 2014;10:641–50.
KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11–145.
Falck S, Adimadhyam S, Meltzer DO, Walton SM, Galanter WL. A trial of indication based prescribing of antihypertensive medications during computerized order entry to improve problem list documentation. Int J Med Inform. 2013;82:996–1003.
Walton SM, Galanter WL, Rosencranz H, et al. A trial of inpatient indication based prescribing during computerized order entry with medications commonly used off-label. Appl Clin Inform. 2011;2:94–103.
Jackson J. FDAMA 1997 section 114: another look. Value Health. 2009;12:191–2.
Neumann PJ. What ever happened to FDAMA section 114? A look back after 10 years. Value Health. 2009;12:189–90.
Dennis B. FDA has free-speech, safety issues to weigh in review of ‘off-label’ drug marketing rules. In: The Washington Post. 2014. http://www.washingtonpost.com/national/health-science/2014/07/09/3708dd6a-fbc4-11e3-8176-f2c941cf35f1_story.html. Accessed 13 Aug 2014.
Afzali HH, Karnon J, Merlin T. Improving the accuracy and comparability of model-based economic evaluations of health technologies for reimbursement decisions: a methodological framework for the development of reference models. Med Decis Making. 2013;33:325–32.
Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Int J Risk Saf Med. 2012;24:137–46.
Abernethy AP, Raman G, Balk EM, et al. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med. 2009;150:336–43.
Conflict of interest statement
The authors received no funding related to this editorial and have no conflicts of interest with regard to this topic.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Walton, S.M., Schumock, G.T. Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies?. PharmacoEconomics 32, 1035–1037 (2014). https://doi.org/10.1007/s40273-014-0222-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-014-0222-2